guest ::
| Home > Publications database > Real-world evidence for an association of vitamin D supplementation with atherosclerotic cardiovascular disease in the UK Biobank. > print |
| Home > Publications database > Real-world evidence for an association of vitamin D supplementation with atherosclerotic cardiovascular disease in the UK Biobank. > print |
| 001 | 300647 | ||
| 005 | 20250427020303.0 | ||
| 024 | 7 | _ | |a 10.1016/j.clnu.2025.04.017 |2 doi |
| 024 | 7 | _ | |a pmid:40267517 |2 pmid |
| 024 | 7 | _ | |a 0261-5614 |2 ISSN |
| 024 | 7 | _ | |a 1532-1983 |2 ISSN |
| 024 | 7 | _ | |a altmetric:176309980 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2025-00858 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Sha, Sha |0 P:(DE-He78)1d6f6305a65e2f7de2c7fbffbae83780 |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a Real-world evidence for an association of vitamin D supplementation with atherosclerotic cardiovascular disease in the UK Biobank. |
| 260 | _ | _ | |a Amsterdam [u.a.] |c 2025 |b Elsevier |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1745498279_21318 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #EA:C070#LA:C070# |
| 520 | _ | _ | |a Atherosclerotic cardiovascular disease (ASCVD) remains a substantial healthcare burden. The Australian D-Health trial recently showed potential efficacy of vitamin D supplementation (VDS) in reducing major ASCVD events. Whether the efficacy could be translated into real-world effectiveness is unclear.Leveraging data from the UK Biobank, we used Cox regression with competing risk of all-cause mortality to assess the association of self-reported regular VDS (83.3 % from over-the-counter) and serum 25-hydroxyvitamin D (25[OH]D) levels with ASCVD as a composite endpoint and as separate endpoints including ischemic heart disease (IHD), cerebrovascular disease, peripheral arterial disease, and atherosclerotic disease.Among 409,822 study participants aged 40-69 years, 20.7 % were vitamin D deficient (25[OH]D < 30 nmol/L) and 34.4 % were vitamin D insufficient (25[OH]D 30-<50 nmol/L). Regular VDS was reported by 4.3 % of the study participants. During the follow-up of 15.9 years, 11.6 % of participants developed ASCVD. Compared to vitamin D sufficiency, vitamin D deficiency was associated with a significantly increased risk of the total ASCVD (hazard ratio [95 % confidence interval]: 1.10 [1.07-1.13]) and all separate ASCVD endpoints in the fully adjusted model with 48 covariates. Consistently, compared to non-users, VDS was associated with a reduced total ASCVD risk in the model fully adjusted for the 50 covariates (0.94[0.90-0.98]). Regarding the individual ASCVD disorders, VDS was associated with reduced IHD risk (0.90[0.86-0.96]).Self-reported regular VDS and being vitamin D sufficient were both associated with reduced ASCVD risk in real-world settings. For people with low 25(OH)D levels, regular VDS may be a beneficial strategy for ASCVD prevention. |
| 536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a 25-hydroxyvitamin D |2 Other |
| 650 | _ | 7 | |a Atherosclerotic cardiovascular disease |2 Other |
| 650 | _ | 7 | |a Real-world evidence |2 Other |
| 650 | _ | 7 | |a Vitamin D supplement use |2 Other |
| 700 | 1 | _ | |a Xie, Ruijie |0 P:(DE-He78)7089188e1b7bdb788ba48ba96f21df07 |b 1 |u dkfz |
| 700 | 1 | _ | |a Gwenzi, Tafirenyika |0 P:(DE-He78)35a941418cdcc6c595b7a8a19e355599 |b 2 |u dkfz |
| 700 | 1 | _ | |a Wang, Youqing |0 P:(DE-He78)5a18ac1d8e95a59d44c072d0a7dba4b7 |b 3 |u dkfz |
| 700 | 1 | _ | |a Brenner, Hermann |0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2 |b 4 |u dkfz |
| 700 | 1 | _ | |a Schöttker, Ben |0 P:(DE-He78)c67a12496b8aac150c0eef888d808d46 |b 5 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1016/j.clnu.2025.04.017 |g Vol. 49, p. 118 - 127 |0 PERI:(DE-600)2009052-3 |p 118 - 127 |t Clinical nutrition |v 49 |y 2025 |x 0261-5614 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:300647 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)1d6f6305a65e2f7de2c7fbffbae83780 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)7089188e1b7bdb788ba48ba96f21df07 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)35a941418cdcc6c595b7a8a19e355599 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)5a18ac1d8e95a59d44c072d0a7dba4b7 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)c67a12496b8aac150c0eef888d808d46 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2024-12-28 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CLIN NUTR : 2022 |d 2024-12-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2024-12-28 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-28 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b CLIN NUTR : 2022 |d 2024-12-28 |
| 920 | 2 | _ | |0 I:(DE-He78)C070-20160331 |k C070 |l C070 Klinische Epidemiologie und Alternf. |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)C070-20160331 |k C070 |l C070 Klinische Epidemiologie und Alternf. |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)C120-20160331 |k C120 |l Primäre Krebsprävention |x 1 |
| 920 | 0 | _ | |0 I:(DE-He78)C070-20160331 |k C070 |l C070 Klinische Epidemiologie und Alternf. |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C070-20160331 |
| 980 | _ | _ | |a I:(DE-He78)C120-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|